Skip to main content
Erschienen in: Pituitary 3/2014

01.06.2014

Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review

verfasst von: Sabrina Chiloiro, Antonio Bianchi, Francesco Doglietto, Chiara de Waure, Antonella Giampietro, Alessandra Fusco, Donato Iacovazzo, Linda Tartaglione, Francesco Di Nardo, Francesco Signorelli, Libero Lauriola, Carmelo Anile, Guido Rindi, Giulio Maira, Alfredo Pontecorvi, Laura De Marinis

Erschienen in: Pituitary | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Ki-67 Labeling Index is an immunocytochemical marker of cell proliferation. The correlation of Ki-67 expression with pituitary adenomas recurrence has been investigated and is highly debated. Aim of this study was to evaluate whether Ki-67 correlates with recurrence even in patients with an apparently completely removed pituitary adenoma. We retrospectively reviewed the database of the Hypothalamic-Pituitary Disease Unit at the Catholic University of Rome, collected between 2003 and 2011. Inclusion criteria were: patients who underwent surgery at the Department of Neurosurgery with an apparently complete removal of a pituitary adenoma; Ki-67 histological evaluation by the same operator and values of <3 %. All patients underwent endocrine evaluation of the hypothalamic-pituitary function, ophthalmologic and neuro-radiological examinations, during the preoperative period and follow-up. Out of 490 patients recorded on the database of the Hypothalamic-Pituitary Disease Unit at the Catholic University of Rome, 191 cases met the inclusion criteria. Recurrence was observed in 49 cases (25.7 % of the patients who had undergone radical excision). Optional cut-off value was identified at Ki-67 values of 1.50 %. This was associated with worse disease-free survival time, even after correction for age at treatment, gender, positivity to p53, functional classification and Knosp grading. Ki-67 labeling index may be useful in postoperative management, even in patients who underwent radical PA removal. We suggest a Ki-67 cut-off value of 1.5 % to plan an adequate clinical follow-up.
Literatur
1.
Zurück zum Zitat Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108(3):525–532CrossRefPubMed Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108(3):525–532CrossRefPubMed
2.
Zurück zum Zitat Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12PubMedCentralCrossRefPubMed Mastronardi L, Guiducci A, Puzzilli F (2001) Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas. BMC Cancer 1:12PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Salehi F, Agur A, Scheithauer BW, Lloyd RV, Cusimano M (2009) Ki-67 in pituitary neoplasms: a review. Part 1. Neurosurgery 65:429–437CrossRefPubMed Salehi F, Agur A, Scheithauer BW, Lloyd RV, Cusimano M (2009) Ki-67 in pituitary neoplasms: a review. Part 1. Neurosurgery 65:429–437CrossRefPubMed
4.
Zurück zum Zitat Burger PC, Shibata T, Kleihues P (1986) The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10:611–617CrossRefPubMed Burger PC, Shibata T, Kleihues P (1986) The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 10:611–617CrossRefPubMed
5.
Zurück zum Zitat Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL (2000) Proliferation, bcl-2, expression and angiogenesis in pituitary adenomas: relationship to tumour behavior. Br J Cancer 82(8):1441–1445PubMedCentralCrossRefPubMed Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL (2000) Proliferation, bcl-2, expression and angiogenesis in pituitary adenomas: relationship to tumour behavior. Br J Cancer 82(8):1441–1445PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F et al (2000) Proliferation index of nonfunctioning pituitary adenomas: correlation with clinical characteristics and longterm follow up results. Neurosurgery 47:1313–1318CrossRefPubMed Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F et al (2000) Proliferation index of nonfunctioning pituitary adenomas: correlation with clinical characteristics and longterm follow up results. Neurosurgery 47:1313–1318CrossRefPubMed
7.
Zurück zum Zitat Fukui S, Otani N, Nawashiro H, Yano A, Nomura N, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K (2002) Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol 19:23–29CrossRefPubMed Fukui S, Otani N, Nawashiro H, Yano A, Nomura N, Miyazawa T, Ohnuki A, Tsuzuki N, Katoh H, Ishihara S, Shima K (2002) Subcellular localization of basic fibroblast growth factor and fibroblast growth factor receptor 1 in pituitary adenomas. Brain Tumor Pathol 19:23–29CrossRefPubMed
8.
Zurück zum Zitat Hsu DW, Hakim F, Biller BM et al (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753–761CrossRefPubMed Hsu DW, Hakim F, Biller BM et al (1993) Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 78:753–761CrossRefPubMed
9.
Zurück zum Zitat Ramirez C, Cheng S, Vargas G, Asa S, Ezzat S, Gonzales B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3 and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistichemical study. J Clin Endocrinol Metabolism 97:1745–1751CrossRef Ramirez C, Cheng S, Vargas G, Asa S, Ezzat S, Gonzales B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3 and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistichemical study. J Clin Endocrinol Metabolism 97:1745–1751CrossRef
10.
Zurück zum Zitat Gejman R, Swearingen B, Hedly-Whyte T (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758–766CrossRefPubMed Gejman R, Swearingen B, Hedly-Whyte T (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758–766CrossRefPubMed
11.
Zurück zum Zitat Matuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlation with clinical variables. Neurol Med Chir 52:563–569CrossRef Matuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlation with clinical variables. Neurol Med Chir 52:563–569CrossRef
12.
Zurück zum Zitat Noh TW, Jeong HJ, Lee TS, Kim SH, Lee EJ (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94:4406–4413CrossRefPubMed Noh TW, Jeong HJ, Lee TS, Kim SH, Lee EJ (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94:4406–4413CrossRefPubMed
13.
Zurück zum Zitat Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumor transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol 65(4):536–543CrossRef Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, Colao A, Meduri G, Chanson P (2006) Pituitary tumor transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol 65(4):536–543CrossRef
14.
Zurück zum Zitat Peak K, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki 67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489–494CrossRef Peak K, Kim SH, Song SH, Choi SW, Koh HS, Youm JY, Kim Y (2005) Clinical significance of Ki 67 labeling index in pituitary macroadenoma. J Korean Med Sci 20:489–494CrossRef
15.
Zurück zum Zitat Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G, Foschini MP (2012) A classification tree approach for pituitary adenomas. Hum Pathol 43:1627–1637CrossRefPubMed Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G, Foschini MP (2012) A classification tree approach for pituitary adenomas. Hum Pathol 43:1627–1637CrossRefPubMed
16.
Zurück zum Zitat Abe T, Sanno N, Osamura YR, Matsumoto K (1997) Proliferativepotential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochirur. 139:613–618CrossRef Abe T, Sanno N, Osamura YR, Matsumoto K (1997) Proliferativepotential in pituitary adenomas: measurement by monoclonal antibody MIB-1. Acta Neurochirur. 139:613–618CrossRef
17.
Zurück zum Zitat Mastronardi L, Guiducci A, Spera C, Puzzili F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52:107–111PubMedCentralCrossRefPubMed Mastronardi L, Guiducci A, Spera C, Puzzili F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52:107–111PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different typer of clinically non-secreting pituitary adenomas. Pituitary 1:213–220CrossRefPubMed Schreiber S, Saeger W, Ludecke DK (1999) Proliferation markers in different typer of clinically non-secreting pituitary adenomas. Pituitary 1:213–220CrossRefPubMed
19.
Zurück zum Zitat Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235–243CrossRefPubMed Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37:235–243CrossRefPubMed
20.
Zurück zum Zitat Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, Mehta VS, Das TK (2010) A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol India 58:418–423CrossRefPubMed Rishi A, Sharma MC, Sarkar C, Jain D, Singh M, Mahapatra AK, Mehta VS, Das TK (2010) A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience. Neurol India 58:418–423CrossRefPubMed
21.
Zurück zum Zitat Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montage M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors endocrine-related. Cancer 14:887–900 Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montage M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors endocrine-related. Cancer 14:887–900
22.
Zurück zum Zitat Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labeling index significance in a large series of pituitary tumors: secreting versus non-secreting adenomas. Endocrine Related Cancer 9:103–113CrossRefPubMed Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labeling index significance in a large series of pituitary tumors: secreting versus non-secreting adenomas. Endocrine Related Cancer 9:103–113CrossRefPubMed
23.
Zurück zum Zitat Hentschel SJ, McCutcheon E, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215–219PubMed Hentschel SJ, McCutcheon E, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215–219PubMed
24.
Zurück zum Zitat Dubois S, Guyetant S, Menei P, Rodien P, Fillouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157:141–147CrossRefPubMed Dubois S, Guyetant S, Menei P, Rodien P, Fillouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157:141–147CrossRefPubMed
25.
Zurück zum Zitat Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS (2010) The clinical significance of MIB-1 index in pituitary adenomas. Pituitary 13:337–344CrossRefPubMed Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil JP, Seshadri MS (2010) The clinical significance of MIB-1 index in pituitary adenomas. Pituitary 13:337–344CrossRefPubMed
26.
Zurück zum Zitat Ma W, Ikeda H, Yoshimoto T (2002) Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95:258–265CrossRefPubMed Ma W, Ikeda H, Yoshimoto T (2002) Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95:258–265CrossRefPubMed
27.
Zurück zum Zitat Mete O, Ezzat S, Asa S (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69–R78CrossRefPubMed Mete O, Ezzat S, Asa S (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69–R78CrossRefPubMed
28.
Zurück zum Zitat Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618CrossRefPubMed Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618CrossRefPubMed
29.
Zurück zum Zitat Ferrante E, Ferraroni M, Castrignano T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG (2006) Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155:823–829CrossRefPubMed Ferrante E, Ferraroni M, Castrignano T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG (2006) Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155:823–829CrossRefPubMed
30.
Zurück zum Zitat Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163:193–200CrossRefPubMed Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163:193–200CrossRefPubMed
31.
Zurück zum Zitat Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15:71–83PubMedCentralCrossRefPubMed Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15:71–83PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
33.
Zurück zum Zitat Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93:2746–2750CrossRefPubMed Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93:2746–2750CrossRefPubMed
34.
Zurück zum Zitat Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102–2107PubMed
35.
Zurück zum Zitat Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679CrossRefPubMed Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99:674–679CrossRefPubMed
36.
Zurück zum Zitat Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumor doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir 138:1449–1455CrossRefPubMed Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T (1996) The correlation of Ki-67 staining indices with tumor doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir 138:1449–1455CrossRefPubMed
37.
Zurück zum Zitat Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas and carcinomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMed Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas and carcinomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98:359–365CrossRefPubMed
38.
Zurück zum Zitat Zhao D, Tomono Y, Nose T (1999) Expression of P27kip1 and Ki- 67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir 141:187–192CrossRefPubMed Zhao D, Tomono Y, Nose T (1999) Expression of P27kip1 and Ki- 67 in pituitary adenomas: an investigation of marker of adenoma invasiveness. Acta Neurochir 141:187–192CrossRefPubMed
39.
Zurück zum Zitat Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA (2006) Expression of p53, Ki-67 and c-erb B2 in growth hormone–and/or prolactin—secreting pituitary adenomas. Arq Neuropsiquiatr 64:60–66CrossRefPubMed Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA (2006) Expression of p53, Ki-67 and c-erb B2 in growth hormone–and/or prolactin—secreting pituitary adenomas. Arq Neuropsiquiatr 64:60–66CrossRefPubMed
40.
Zurück zum Zitat Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analysis of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 49:1193–1194CrossRefPubMed Nakabayashi H, Sunada I, Hara M (2001) Immunohistochemical analysis of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 49:1193–1194CrossRefPubMed
Metadaten
Titel
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review
verfasst von
Sabrina Chiloiro
Antonio Bianchi
Francesco Doglietto
Chiara de Waure
Antonella Giampietro
Alessandra Fusco
Donato Iacovazzo
Linda Tartaglione
Francesco Di Nardo
Francesco Signorelli
Libero Lauriola
Carmelo Anile
Guido Rindi
Giulio Maira
Alfredo Pontecorvi
Laura De Marinis
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 3/2014
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0500-6

Weitere Artikel der Ausgabe 3/2014

Pituitary 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.